Norepinephrine-dopamine reuptake inhibitor
This page covers all Norepinephrine-dopamine reuptake inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dopamine transporter, Norepinephrine transporter, Norepinephrine transporter, Dopamine transporter.
Targets
Dopamine transporter, Norepinephrine transporter · Norepinephrine transporter, Dopamine transporter
Marketed (4)
- "Conventional" regimen · Pablo Rodríguez del Rio · Psychiatry
This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine. - Habitual medication · Hospital Universitario de Canarias · Psychiatry
This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine. - A2 · Breath of Life International Pharma Ltd · Psychiatry
A2 is a medication that works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine. - bupropion immediate release (IR) · Pfizer · Neuroscience
Phase 3 pipeline (2)
- Switching: Bupropion-SR · VA Office of Research and Development · Psychiatry
Bupropion-SR is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain. - bupropion and transdermal patch · US Department of Veterans Affairs · Mental health, Smoking cessation
Bupropion is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain.
Phase 2 pipeline (1)
- Bupropion Sustained Release · Iowa City Veterans Affairs Medical Center · Neurology
Norepinephrine-dopamine reuptake inhibitor
Patent intelligence
- norepinephrine dopamine reuptake inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates